Results 161 to 170 of about 1,468,668 (317)
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
W-Band Through-Wall Radar Using a High-Gain Frequency-Scanning SSPP Antenna. [PDF]
Tian Z +6 more
europepmc +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
High gain quad-port circularly polarized aperture-coupled MIMO antenna. [PDF]
Abdelhady AM +3 more
europepmc +1 more source
High Gain Artificial Magnetic Conductor Integrated Antenna for Wi-Fi 6E/Automotive Radar Systems Applications [PDF]
Kanuri Naveen, D. Vakula
openalex +1 more source
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan +9 more
wiley +1 more source
Integration of fast charging EV infrastructure with high gain Z-source converters and hybrid optimized MPPT algorithm. [PDF]
Sathish R, Sekar V.
europepmc +1 more source
High-gain lithium niobate brillouin laser with tunable phonon frequency of 1∼31 GHz [PDF]
Huibo Liu +6 more
openalex +1 more source
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts +8 more
wiley +1 more source

